{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:47:18Z","timestamp":1791996438538,"version":"4.4.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004356","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000}}],"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL144406"],"award-info":[{"award-number":["R01HL144406"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance and completion of 3HP could be achieved with delivery strategies optimized to overcome well-contextualized barriers and that 3HP acceptance and completion would be highest when PLHIV were provided an informed choice between delivery strategies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>In a pragmatic, single-center, 3-arm, parallel-group randomized trial, PLHIV receiving care at a large urban HIV clinic in Kampala, Uganda, were randomly assigned (1:1:1) to receive 3HP by facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between facilitated DOT and facilitated SAT using a shared decision-making aid. We assessed the primary outcome of acceptance and completion (\u226511 of 12 doses of 3HP) within 16 weeks of treatment initiation using proportions with exact binomial confidence intervals (CIs). We compared proportions between arms using Fisher\u2019s exact test (two-sided \u03b1 = 0.025). Trial investigators were blinded to primary and secondary outcomes by study arm. Between July 13, 2020, and July 8, 2022, 1,656 PLHIV underwent randomization, with equal numbers allocated to each study arm. One participant was erroneously enrolled a second time and was excluded in the primary intention-to-treat analysis. Among the remaining 1,655 participants, the proportion who accepted and completed 3HP exceeded the prespecified 80% target in the DOT (0.94; 97.5% CI [0.91, 0.96] <jats:italic>p<\/jats:italic> &lt; 0.001), SAT (0.92; 97.5% CI [0.89, 0.94] <jats:italic>p<\/jats:italic> &lt; 0.001), and Choice (0.93; 97.5% CI [0.91, 0.96] <jats:italic>p<\/jats:italic> &lt; 0.001) arms. There was no difference in acceptance and completion between any 2 arms overall or in prespecified subgroup analyses based on sex, age, time on antiretroviral therapy, and history of prior treatment for TB or TB infection. Only 14 (0.8%) participants experienced an adverse event prompting discontinuation of 3HP. The main limitation of the study is that it was conducted in a single center. Multicenter studies are now needed to confirm the feasibility and generalizability of the facilitated 3HP delivery strategies in other settings.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Short-course TB preventive treatment was widely accepted by PLHIV in Uganda, and very high levels of treatment completion were achieved in a programmatic setting with delivery strategies tailored to address known barriers.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial Registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03934931\" xlink:type=\"simple\">NCT03934931<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004356","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:35:21Z","timestamp":1708454121000},"page":"e1004356","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial"],"prefix":"10.1371","volume":"21","author":[{"given":"Fred C.","family":"Semitala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-8681","authenticated-orcid":true,"given":"Jillian L.","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-6433","authenticated-orcid":true,"given":"Allan","family":"Musinguzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Welishe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Nakitende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Akello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kunihira Tinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Nakimuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-462X","authenticated-orcid":true,"given":"Joan","family":"Ritar Kasidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opira","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2655-4744","authenticated-orcid":true,"given":"Suzan","family":"Nakasendwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonsoo","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-3588","authenticated-orcid":true,"given":"Devika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Sammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Belknap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-4234","authenticated-orcid":true,"given":"Moses R.","family":"Kamya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":true,"given":"Patrick PJ","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3520-070X","authenticated-orcid":true,"given":"Anne","family":"Katahoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0034-7544","authenticated-orcid":true,"given":"Christopher A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kiwanuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Katamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-7475","authenticated-orcid":true,"given":"David W.","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-2601","authenticated-orcid":true,"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"pmed.1004356.ref001","volume-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022"},{"key":"pmed.1004356.ref002","article-title":"Treatment of latent tuberculosis infection in HIV infected persons.","author":"C Akolo","journal-title":"Cochrane HIV\/AIDS Group, editor. Cochrane Database Syst Rev"},{"issue":"9","key":"pmed.1004356.ref003","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa","volume":"373","author":"TEMPRANO ANRS 12136 Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"pmed.1004356.ref004","volume-title":"The End TB Strategy: Global strategy and targets for tuberculosis prevention, care and control after 2015","year":"2014"},{"key":"pmed.1004356.ref005","author":"Global Tuberculosis Report","year":"2023","journal-title":"World Health Organization"},{"issue":"12","key":"pmed.1004356.ref006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.15585\/mmwr.mm6912a3","article-title":"Tuberculosis Preventive Treatment Scale-Up Among Antiretroviral Therapy Patients\u201416 Countries Supported by the U.S. President\u2019s Emergency Plan for AIDS Relief, 2017\u20132019.","volume":"69","author":"M Melgar","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep. 2020\/03\/28 ed"},{"issue":"23","key":"pmed.1004356.ref007","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"TR Sterling","year":"2011","journal-title":"N Engl J Med. 2011\/12\/14 ed"},{"key":"pmed.1004356.ref008","volume-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"World Health Organization, others","year":"2018"},{"issue":"10","key":"pmed.1004356.ref009","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial","volume":"167","author":"R Belknap","year":"2017","journal-title":"Ann Intern Med. 2017\/11\/09 ed"},{"issue":"10","key":"pmed.1004356.ref010","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.7326\/M20-7577","article-title":"Annual Tuberculosis Preventive Therapy for Persons With HIV Infection: A Randomized Trial.","volume":"174","author":"G Churchyard","year":"2021","journal-title":"Ann Intern Med. 2021\/08\/24 ed"},{"issue":"3","key":"pmed.1004356.ref011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","article-title":"Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.","volume":"50","author":"GM Curran","year":"2012","journal-title":"Med Care. 2012\/02\/09 ed"},{"issue":"1","key":"pmed.1004356.ref012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13012-020-01025-8","article-title":"Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.","volume":"15","author":"JL Kadota","year":"2020","journal-title":"Implement Sci. 2020\/08\/14 ed"},{"key":"pmed.1004356.ref013","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"KF Schulz","year":"2010","journal-title":"BMJ"},{"issue":"7","key":"pmed.1004356.ref014","doi-asserted-by":"crossref","first-page":"729","DOI":"10.5588\/ijtld.20.0010","article-title":"Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy","volume":"24","author":"JL Kadota","year":"2020","journal-title":"Int J Tuberc Lung Dis. 2020\/07\/29 ed"},{"issue":"2","key":"pmed.1004356.ref015","doi-asserted-by":"crossref","first-page":"e0246113","DOI":"10.1371\/journal.pone.0246113","article-title":"Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda","volume":"16","author":"RK Lim","year":"2021","journal-title":"PLoS ONE. 2021\/02\/05 ed"},{"issue":"1","key":"pmed.1004356.ref016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s43058-021-00173-2","article-title":"Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda\u2014patient and health worker perspectives.","volume":"2","author":"FC Semitala","year":"2021","journal-title":"Implement Sci Commun."},{"key":"pmed.1004356.ref017","first-page":"7","article-title":"Applying COM-B to medication adherence: A suggested framework for research and interventions.","volume":"16","author":"C Jackson","year":"2014","journal-title":"Eur Health Psychol."},{"key":"pmed.1004356.ref018","unstructured":"Official exchange rate (LCU per US$, period average)\u2014Uganda [Internet]. [accessed 2023 Feb 13]. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF?locations=UG."},{"issue":"8","key":"pmed.1004356.ref019","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.","volume":"61","author":"AT Podany","year":"2015","journal-title":"Clin Infect Dis. 2015\/06\/18 ed"},{"issue":"9","key":"pmed.1004356.ref020","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","article-title":"Evaluating the public health impact of health promotion interventions: the RE-AIM framework.","volume":"89","author":"RE Glasgow","year":"1999","journal-title":"Am J Public Health. 1999\/09\/04 ed"},{"key":"pmed.1004356.ref021","author":"National Strategic Plan for Tuberculosis and Leprosy Control 2020\/21\u20132024\/25","year":"2020","journal-title":"Uganda: National TB and Leprosy Control Program;"},{"issue":"12","key":"pmed.1004356.ref022","doi-asserted-by":"crossref","first-page":"e1003875","DOI":"10.1371\/journal.pmed.1003875","article-title":"Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.","volume":"18","author":"FC Semitala","year":"2021","journal-title":"PLoS Med. 2021\/12\/17 ed"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004356","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T18:33:06Z","timestamp":1709663586000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004356"}},"subtitle":[],"editor":[{"given":"Claudia M.","family":"Denkinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004356","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004356","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}